Skip navigation
Watchlist Sponsored By :

As of Friday, November 13th:
The blended earnings growth rate for the S&P 500 for Q3 2009, combining actual numbers for companies that have reported, and estimates for companies yet to report rose to -13.8% from -13.9% in the previous day.
As of October 1st, the earnings growth rate was at -24.7%.Of the 463 S&P 500 companies who have reported Q3, 80% beat estimates, 6% were in-line, and 14% were below estimates.  The blended earnings growth rate for the S&P 500 for Q3 2009 is currently at -13.8%. (Data provided by Thomson Reuters)

LATEST EARNINGS RESULTS


Current DateTime: 04:54:31 14 Nov 2009
LinksList Documentid: 29017166
Expiration DateTime: 11/14/2009 4:57:26 PM

Current DateTime: 04:54:32 14 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 04:54:32 14 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 04:54:32 14 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Gilead HIV Drugs Drive Profit After Year-Ago Loss
By: Reuters | 18 Oct 2007 | 07:17 PM ET
Text Size

Gilead Sciences posted a third-quarter profit that topped Wall Street targets on Thursday, on sales of drugs that fight the virus that causes AIDS, compared with a year-ago net loss due to acquisition-related costs.

The fast-growing company, which named former Avaya [AV  Loading...      ()   ] and Merck & Co [MRK  Loading...      ()   ] executive Caroline Dorsa chief financial officer, now expects 2007 product revenue to land at the high end of its existing forecast range of $3.6 billion to $3.7 billion.

Foster City, California-based Gilead  reported a profit of $398.3 million, or 42 cents per share, compared with a loss of $52.2 million, or 6 cents per share, a year earlier, when the company took a large charge for its purchase of Corus Pharma.

Analysts, on average, had seen Gilead posting a profit of 39 cents per share, according to Reuters Estimates.

Total revenue grew 41 percent to $1.06 billion, helped by product revenue that increased 44 percent to $961.9 million during the quarter.

Sales of HIV drugs rose 45 percent to $805.8 million, which included a 32 percent jump in sales of the two-drug combination medicine Truvada to $409.1 million.

Sales of the newer Atripla, which combines Truvada with Bristol-Myers Squibb's [BMY  Loading...      ()   ] Sustiva into a single pill, more than tripled to $241.1 million from $68.4 million in the year-ago period.

On Thursday, the European Medicines Agency said it recommended approval for Atripla. Company executives said on a conference call that final clearance could come before the end of the year.

That news comes a day after Canadian drug regulators approved Atripla for the treatment of HIV infection in adults.

Royalty, contract and other revenue rose 23 percent to $96.9 million. Gilead gets much of its royalty revenue from Roche Holding's sales of Tamiflu flu treatment.

As Roche reported earlier this week, third-quarter Tamiflu sales fell 60 percent following completion of orders for influenza pandemic stockpiles. 

Gilead shares [GILD  Loading...      ()   ] closed up 1.9 percent at $43.51 on the Nasdaq prior to the company's financial report, but were just slightly lower at $43.35, in extended trading.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon

Current DateTime: 04:54:32 14 Nov 2009
LinksList Documentid: 29016957
Expiration DateTime: 11/14/2009 4:55:57 PM

Current DateTime: 04:54:32 14 Nov 2009
LinksList Documentid: 29017287
Expiration DateTime: 11/14/2009 4:55:27 PM


Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters